Versantis is a clinical-stage company developing transformative orphan drugs that fill the medical gap in the care of liver and pediatric diseases. It has been acquired by GENFIT in 2022.
Products, services, technology
VS-01-ACLF phase 2a-ready; FDA orphan-designated in acute-on-chronic liver failure. VS-01-UCD preclinical-stage; FDA orphan-designated in acute pediatric hyperammonemia. VS-02 oral, small molecule for chronic hepatic encephalopathy (HE). TS-01 point-of-care diagnostic device to manage HE at home.